| Literature DB >> 17449174 |
O Gautschi1, B Huegli, A Ziegler, M Gugger, J Heighway, D Ratschiller, P C Mack, P H Gumerlock, H J Kung, R A Stahel, D R Gandara, D C Betticher.
Abstract
Because of the current controversy on the origin and clinical value of circulating KRAS codon 12 mutations in lung cancer, we screened 180 patients using a combined restriction fragment-length polymorphism and polymerase chain reaction (RFLP-PCR) assay. We detected KRAS mutations in 9% plasma samples and 0% matched lymphocytes. Plasma KRAS mutations correlated significantly with poor prognosis. We validated the positive results in a second laboratory by DNA sequencing and found matching codon 12 sequences in blood and tumor in 78% evaluable cases. These results support the notion that circulating KRAS mutations originate from tumors and are prognostically relevant in lung cancer.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17449174 DOI： 10.1016/j.canlet.2007.03.008
Source DB: PubMed Journal: Cancer Lett ISSN： 0304-3835 Impact factor: 8.679